Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6053636 | 0.88 | HSD17B10 (0.41) | KDM4EALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL5221921 | 0.83 | XDH (0.41) | CYP11B2CYP11B1KDM4EALDH1A1HPGD | |
| SCHEMBL5219920 | 0.80 | CYP1A2 (0.43) | KDM4EALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL5214483 | 0.79 | CYP11B2 (0.58) | CYP11B2CYP11B1KDM4EALDH1A1CYP2C9 | |
| SCHEMBL5219763 | 0.78 | CYP11B2 (0.70) | CYP11B2CYP11B1 | |
| SCHEMBL6053580 | 0.73 | FDFT1 (0.40) | KDM4EALDH1A1HPGDCYP2C9CYP2C19 | |
| SCHEMBL31181709 | 0.73 | CYP2C9 (0.49) | CYP11B2CYP11B1ALDH1A1HPGDCYP2C9 | |
| SCHEMBL19065487 | 0.73 | CYP2C9 (0.49) | CYP11B2CYP11B1ALDH1A1HPGDCYP2C9 | |
| SCHEMBL7603924 | 0.72 | CASR (0.52) | S1PR1 | |
| SCHEMBL7603925 | 0.72 | CASR (0.52) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368318-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| US-6864267-B2 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1368318-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030212110-A1 | Glandular disorders; bone disorders | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2002007673-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212110-A1 | Glandular disorders; bone disorders | CYP24A1, PTH1R, SOST | CYP11B2 1469/4885CYP11B1 1806/4885KDM4E 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.